TRDA - Entrada Therapeutics, Inc.
About Entrada Therapeutics, Inc. (https://www.entradatx.com)
Entrada Therapeutics, Inc. operates as a biotechnology enterprise dedicated to pioneering endosomal escape vehicle (EEV) therapeutics, specifically engineered to tackle a range of neuromuscular ailments. The company leverages its proprietary EEV platform to cultivate a rich pipeline of therapeutic programs, integrating oligonucleotide, antibody, and enzyme-based approaches. Its foremost product candidate, ENTR-601-44, is currently undergoing preclinical assessment for its potential in addressing both Duchenne muscular dystrophy and myotonic dystrophy type 1. Furthermore, Entrada is actively developing EEV-PMO-CAG, also targeting myotonic dystrophy type 1. Incorporated in 2016, the firm was formerly known as CycloPorters, Inc., before officially changing its name to Entrada Therapeutics, Inc. in October 2017. The company maintains its corporate headquarters in Boston, Massachusetts.
Key Executives
| NAME | TITLE | DOB | SALARY |
|---|---|---|---|
| Dipal Doshi | Chief Executive Officer & Director | 1976 | $998,250 USD |
| Natarajan Sethuraman | President of Research & Development | 1962 | $768,000 USD |
| Nathan J. Dowden | President & Chief Operating Officer | 1971 | $737,182 USD |
| Jared Cohen | General Counsel | – | – |
| Karla MacDonald | Chief Corporate Affairs Officer | – | – |
| Kerry Robert | Senior Vice President of People | – | – |
| Kevin Healy | Senior Vice President of Regulatory Affairs | – | – |
| Kory James Wentworth | Chief Financial Officer & Treasurer | 1979 | – |
| Sandeep Basnet | Head of Information Technology | – | – |